Green Valley’s Oligomannate Approved for Alzheimer’s Disease Treatment in China Representing the First AD Approval in Decades

Green Valley’s Oligomannate Approved for Alzheimer’s Disease Treatment in China Representing the First AD Approval in Decades

Shanghai China’s Green Valley Pharmaceuticals (Green Valley) received approval from the China National Medical Products Administration (NMPA) for their Oligomannate (GV-971) as a new drug for the treatment of mild to moderate Alzheimer’s disease (AD) and improving...

Pin It on Pinterest